Trinity Industries (NYSE:TRN) Q4 2025 Earnings call February 12, 2026 08:00 AM ET Speaker5Good day, and welcome to the Trinity Industries fourth quarter and full year ended December 31, 2025 results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing Star, then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press Star, then one on your ...

Q4'25 & FY'25 Earnings Results Q4'25 & FY'25 Summary 9 Ground Leases $167m Investment Activity1,2 S&P Ratings Upgrade to A- Safehold now A3 / A- / A- rated by Moody's, S&P and Fitch 1 Leasehold Loan $400m Unsecured Term Loan Increases liquidity and flexibility; repaid nearest-term 2027 debt Q4'25 Highlights Q4'25 & FY'25 Investments | | Q4'25 | FY'25 | | --- | --- | --- | | | (9 GLs, 1 Loan) | (17 GLs, 4 Loans) | | Ground Lease Originations1 | $112m | $277m | | Leasehold Loan Originations2 | $55m | $152m | ...

Free Cash Generation of R$2.8 billion and leverage of 2.56x (vs guidance of 2.60x) Gross profit optimization, focus on expense control, and financial discipline EARNINGS RESULTS 4 TH QUARTER 2025 FEBRUARY 12 TH, 2026 • Free Cash Generation: R$ 2.8 billion • 84% EBITDA to cash conversion • 2.56x, below guidance (2.60x) • Reduction in Net Debt: R$1.2 billion • R$84.7 billion (+5.2%) • SSS excl. Calendar effect: +2.6% • +10 new stores, 312 in operation • Pre-IFRS 16 EBITDA: R$4.5 bi | Margin 5.8% (+0.2 p.p.) • ...

Fourth Quarter and Full Year 2025 Financial Results Michael J. Brown | Chairman, CEO and President Rick Weller | EVP & CFO Adam Godderz | General Counsel Euronet | www.euronet.com 1 020626-1 Forward Looking Statements Statements contained in this news release that concern Euronet's or its management's intentions, expectations, or predictions of future performance, are forward-looking statements. Euronet's actual results may vary materially from those anticipated in such forward-looking statements as a resul ...

Fourth Quarter & Full Year 2025 Earnings Conference Call February 12, 2026 CAUTIONARY STATEMENT This presentation includes statements that are not historical facts and are "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements are based on management's current assumptions, estimates and expectations, including with respect to our financial and operational outlook (sales, adjusted operating EBITDA and cash flow), portfolio opt ...

Commerce.com (NasdaqGM:BIGC) Q4 2025 Earnings call February 12, 2026 08:00 AM ET Speaker8Ladies and gentlemen, thank you for standing by, and welcome to the Commerce fourth quarter and fiscal year 2025 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your first speaker today, Tyler Duncan, Senior Vi ...

Fourth Quarter 2025 Franklin BSP Realty Trust Supplemental Information Important Information The information herein relates to the Company's business and financial information as of December 31, 2025 and does not reflect subsequent developments. Risk Factors Investing in and owning our common stock involves a high degree of risk. For a discussion of these risks, see the section entitled "Risk Factors" in our Annual Report on Form 10- K filed with the SEC on February 26, 2025, and the risk disclosures in our ...

Financial Data and Key Metrics Changes - In Q4 2025, Agios Pharmaceuticals reported worldwide PYRUKYND revenue of $20 million, an increase of 86% compared to Q4 2024, and a sequential increase of 55% from $13 million in Q3 2025 [9][10] - Full-year 2025 revenue for PYRUKYND reached $54 million, reflecting robust year-on-year growth [5][9] - The company ended Q4 2025 with approximately $1.2 billion in cash, cash equivalents, and marketable securities, providing flexibility for future investments [6][10] Business Line Data and Key Metrics Changes - U.S. fourth quarter revenues for PYRUKYND were $16 million, driven by commercial focus in PK deficiency and favorable growth adjustments [9] - Ex-U.S. revenue was $4 million in Q4, primarily reflecting inventory stocking ahead of demand [10] - Cost of sales for Q4 was $1.9 million, R&D expenses were $88.1 million, and SG&A expenses were $51.6 million, roughly flat year-on-year [10] Market Data and Key Metrics Changes - The ACTIVASE launch for thalassemia in the U.S. is underway, with expectations for U.S. PK deficiency revenues in 2026 to be in the range of $45-$50 million [9][10] - The company anticipates a sequential decline in ex-U.S. revenues into Q1 2026 due to inventory adjustments [10] Company Strategy and Development Direction - The company outlined its 2026 strategic priorities, focusing on executing the ACTIVASE launch, expanding the PK activation franchise, advancing early-stage pipeline programs, and maintaining financial discipline [4][5] - Agios aims to leverage its capital-efficient global commercial model to focus investments on the U.S. market, which presents the most significant revenue opportunity [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early demand for ACTIVASE, noting strong engagement from physicians and a healthy breadth of early prescribers [14][40] - The company sees a clear path to profitability through its existing commercial presence in thalassemia and PK deficiency, with operating expenses expected to remain flat in 2026 [11][68] Other Important Information - The company received FDA approval for ACTIVASE on December 23, 2025, and the U.S. launch is underway with positive early feedback from physicians [18][19] - Enrollment in the phase II sickle cell disease trial of tebapivat is complete, with top-line results expected in the second half of 2026 [6][20] Q&A Session Summary Question: How does the ACTIVASE launch translate to treatment initiation and revenue recognition? - Management indicated that prescriptions are expected to grow ahead of revenues due to a 10-12 week conversion time from prescription to treatment initiation [29][30] Question: What are the expectations for the phase II data in sickle cell disease? - Management expressed excitement about the trial, noting that it is a dose-finding study aimed at exploring hemoglobin response [34][35] Question: What is the payer mix for ACTIVASE and how does it affect revenue? - The payer mix is similar to PK deficiency, with most patients under commercial payers, and initial market access will occur through medical exceptions [90] Question: What is the rationale for higher dosing in lower-risk MDS compared to sickle cell disease? - Higher doses in MDS are due to faster metabolism in MDS patients, while sickle cell patients metabolize the drug similarly to healthy volunteers [98] Question: What is the expected timeline for profitability? - Management has not provided specific timing but indicated that thalassemia presents a meaningful opportunity for profitability [68][70]

Nebius Group (NasdaqGS:NBIS) Q4 2025 Earnings call February 12, 2026 08:00 AM ET Speaker6Welcome to Nebius Group's Q4 2025 Earnings Conference Call. The presentation will be followed by a Q&A session. If you would like to ask a question, you can click the Ask a Question tab in the top right of the live stream player. Then just type in your question and click Submit. You can submit questions at any time during the presentation, and the Nebius management team will try and answer as many questions as they can ...

Materion Corporation 4Q 2025 Earnings Presentation February 12, 2026 © 2026 Materion Corporation | Agenda | | | --- | --- | | Introduction | Kyle Kelleher – Director, Investor Relations and Corporate FP&A | | Opening Remarks & Business Update | Jugal Vijayvargiya – President and Chief Executive Officer | | Financial Review | Shelly Chadwick – Vice President and Chief Financial Officer | | Q&A | Question and Answer Session | 2 © 2026 Materion Corporation Forward-looking Statements and Non-GAAP Financial Info ...